Beyond Cancer Reports Extended Survival in Late-Stage Trial, Secures Key Patent
Event summary
- Phase 1 UNO trial data presented at AACR 2026 show 60% survival rate (22–40 months) in heavily pretreated patients after single intratumoral injection.
- US patent allowance granted for proprietary gas delivery technology, strengthening IP portfolio.
- Trial enrolled 10 patients with breast cancer (60%), squamous cell carcinoma (20%), and melanoma (20%), all with median 4 prior therapies.
- One treatment-related serious adverse event (hypoxia) occurred but resolved fully; no dose-limiting toxicity observed.
- Median overall survival not yet reached as >50% of patients remain alive at last follow-up.
The big picture
Beyond Cancer’s Phase 1 data suggests potential for ultra-high concentration nitric oxide (UNO) as a salvage therapy in heavily pretreated cancer patients, a population with limited options. The survival signals, though preliminary, position UNO as a candidate for combination strategies with immune checkpoint inhibitors. The patent allowance further solidifies Beyond Air’s IP moat in nitric oxide delivery technologies, critical as the company navigates both respiratory and oncology applications.
What we're watching
- Clinical Validation
- Whether prolonged survival signals in salvage-stage patients can translate to earlier treatment lines or combination therapies.
- Regulatory Pathway
- The pace at which Beyond Cancer advances UNO into larger, controlled trials given the promising but limited Phase 1 data.
- IP Strategy
- How the newly allowed patent strengthens Beyond Cancer’s competitive position in nitric oxide-based cancer therapies.
Related topics